Jonathan Yang
NYU Langone Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jonathan Yang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:35 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07674693 · Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal MetastasesNYU Langone Health · not yet recruiting · Leptomeningeal Metastases · principal investigator
- Ph1NCT07457307 · Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-LinacNYU Langone Health · not yet recruiting · High-grade Glioma · principal investigator
- Early Ph1NCT06829173 · Concurrent XRD-0394 With Radiation Therapy for High Grade GliomasNYU Langone Health · recruiting · High-Grade Glioma · principal investigator
- Ph1NCT06724926 · Concurrent Azeliragon With Craniospinal IrradiationNYU Langone Health · active not recruiting · Solid Tumor, High-grade Glioma, Leptomeningeal Metastasis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:35 UTC. The ranking covers the 200 most relevant of 2607 PubMed records, and a shared surname and initials can bring in a namesake. All 2607 on PubMed
- 441 citationsRCR 52.6
- 320 citationsRCR 34.5
- Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.N Engl J Med · 2024298 citationsRCR 34.6
- 221 citationsRCR 22.1
- Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke.N Engl J Med · 2024170 citationsRCR 31.0
- 169 citationsRCR 16.1
- 163 citationsRCR 28.4
- CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.J Clin Oncol · 2024146 citationsRCR 15.6
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.J Hepatol · 2025142 citationsRCR 39.3
- Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.N Engl J Med · 2025135 citationsRCR 26.4